<SEC-DOCUMENT>0001213900-20-006736.txt : 20200318
<SEC-HEADER>0001213900-20-006736.hdr.sgml : 20200318
<ACCEPTANCE-DATETIME>20200318082641
ACCESSION NUMBER:		0001213900-20-006736
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200318
FILED AS OF DATE:		20200318
DATE AS OF CHANGE:		20200318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		20723261

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea119753-6k_enlivex.htm
<DESCRIPTION>CURRENT REPORT OF FOREIGN ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the month of: March 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant&rsquo;s name into
English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On March 18, 2020, Enlivex
Therapeutics Ltd., a company organized under the laws of the State of Israel (the &ldquo;<U>Company</U>&rdquo;), issued a press
release with respect to final analysis of safety and efficacy data from the Company&rsquo;s completed Phase Ib clinical trial of
off-the-shelf Allocetra<SUP>TM</SUP> in patients with severe sepsis. A copy of such press release is furnished as Exhibit 99.1
to this Report on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%">99.1</TD>
    <TD STYLE="width: 2%"></TD>
    <TD STYLE="width: 93%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="ea119753ex99-1_enlivex.htm">Press Release issued by Enlivex Therapeutics Ltd. on March 18, 2020.</A></P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">Enlivex Therapeutics Ltd.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">(Registrant)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 6%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 35%">/s/ Shai Novik</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>Name:<BR>
Title:</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Shai Novik<BR>Executive Chairman</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">Date:
March 18, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea119753ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON MARCH 18, 2020.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 16pt">Enlivex
Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ndash; Final Analysis Comparing 10
Allocetra<FONT STYLE="font-size: 8pt"><SUP>TM</SUP></FONT>-Treated Patients with 37 Matched Controls Showed Significant Positive
Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly Fragile and Extremely Difficult to Treat Population
with Severe Sepsis&nbsp;&ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Nes Ziona, Israel, March 18, 2010
(GLOBE NEWSWIRE) &mdash; Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced positive
final safety and efficacy data from the Company&rsquo;s completed Phase Ib clinical trial in patients with severe sepsis. The
final analysis compared the clinical data of 10 patients admitted to the intensive care unit with sepsis who were administered
off-the-shelf Allocetra<FONT STYLE="font-size: 8pt"><SUP>TM</SUP></FONT> (&ldquo;Allocetra-OTS&rdquo;) upon their admission, with
37 patients who were matched controls (matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection
source) who received only the standard of care treatment at the same hospital during 2014-2019 but did not receive Allocetra-OTS.
The clinical trial was conducted at Hadassah Medical Center, which is one of the largest and most prestigious hospitals in Israel
(&ldquo;Haddasah&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The primary aim of the clinical trial
was to determine the safety profile and tolerability of. In addition, effects on, mortality, organ dysfunction and number of hospitalization
days in general and in the intensive care unit (ICU) were measured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Mortality</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Acute Physiology and Chronic Health
Evaluation (APACHEII) score of the Allocetra OTS-treated group was 12.3, and the corresponding probability of mortality of at least
one patient in that group was predicted at 85% based on the hospital&rsquo;s ICU staff&rsquo;s clinical assessment of each patient&rsquo;s
overall condition at admission. However, none (0%) of the Allocetra-OTS-treated patients died during the 28-day study period, as
compared to 27% 28-day mortality in the matched controls group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Sepsis &amp; Organ Failure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Each of the 10 Allocetra-OTS-treated
patients had between 2 to 5 dysfunctional organ systems upon admission to the ICU. All (100%) of the Allocetra-OTS-treated patients
had rapid and complete recovery from their septic conditions and of any organ dysfunction that was present upon admission to the
ICU. Despite the similarity of organ-failure state (SOFA) at entry between the Allocetra-OTS-treated patients and the matched controls
group (average of 3.4 versus 3.47), not a single patient treated with Allocetra-OTS had any increase in organ-failure state post
administration of Allocetra-OTS, while the majority of the patients in the matched controls group had an increase in organ-failure
state. The average worsening in organ-failure state of patients in the matched controls group was approximately 100% compared with
their ICU hospitalization state vs zero (0%) percent worsening in organ-failure state of Allocetra-OTS-treated patients post administration
of Allocetra-OTS (p&lt; &lt;0.0001).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Duration of ICU Hospitalization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The ICU length-of-stay for all Allocetra-OTS-treated
patients was significantly shorter than those patients who received only the standard of care, with an average of 4 days compared
to 11.11 in the matched controls group, a 64% reduction (p&lt;0.0001). The slowest ICU discharge of a patient treated with Allocetra-OTS
was after 8 days, while approximately 50% of the matched controls group were still at the ICU after 28 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Safety</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Allocetra-OTS was shown to be safe
and tolerable, with no serious unexpected severe adverse reactions and no serious adverse events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Prof. Dror Mevorach, Chief Medical
Officer of Enlivex, commented, &ldquo;We were excited to observe such deep and durable responses at a well-tolerated dose in this
highly fragile and extremely difficult to treat septic population, and obtaining statistically-significant differences from the
matched historical controls group. We believe that Allocetra-OTS is positioned as a potentially clinically viable option for treatment
of sepsis, which is a clinical condition that has poor clinical outcomes and no currently effective therapy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Oren Hershkovitz, CEO of Enlivex, stated,
&ldquo;Allocetra-OTS is a significant product candidate for Enlivex, and the robust results of this study are highly encouraging.
We are compiling patient&rsquo;s cytokine storm data in an effort to analyze the potential of Allocetra-OTS in other clinical indications
whose pathophysiology is highly correlated with cytokine storms and exaggerated immune responses.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Study design</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aim of this study was to determine the safety and efficacy
profile and tolerability of Allocetra-OTS, in subjects admitted to the emergency room with sepsis. Allocetra-OTS (140x10<SUP>6</SUP>
cells/kg) was administered in either a single dose to 6 patients at day 1 or in two doses to 4 additional patients at days 1 and
3, to patients admitted to the emergency room with sepsis. Patients were followed for 28 days. The study subjects were also compared
to historical controls hospitalized in the ICU, matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection
source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Sepsis is defined as a life-threatening
organ dysfunction caused by a dysregulated immune response to infection. Sepsis has been identified by the World Health Organization
as a global health priority and currently has no FDA-approved pharmacologic treatment. Sepsis is the third leading cause of mortality
in the United States after cardiovascular and cancer diseases and affects approximately 1.7 million adults in the United States
each year. Various studies have estimated that up to 50% of severe sepsis hospitalizations culminate in death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Allocetra<FONT STYLE="font-size: 8pt"><SUP>TM</SUP></FONT><SUP>&nbsp;</SUP>is
an experimental therapy being investigated for treatment of patients with organ failure associated with sepsis, a syndrome whose
lethal pathophysiology &ndash; hyper stimulation of the immune response and cytokine storm followed by organ failure &ndash; that
may be similar to that of the coronavirus (COVID-19) associated with the newly recognized virus SARS-CoV-2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>ABOUT ENLIVEX</B><BR>
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune
system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression
of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid
tumors immune-checkpoint rebalancing.&nbsp; For more information, visit&nbsp;http://www.enlivex.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Safe Harbor Statement:&nbsp; This
press release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo;
&ldquo;would&rdquo;, &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the
potential to&rdquo; and other words of similar meaning, including statements regarding expected cash balances, market opportunities
for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<FONT STYLE="font-size: 8pt"><SUP>TM</SUP></FONT>&nbsp;programs.
All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995.&nbsp; Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex&rsquo;s
business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial
products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate
data that would support the approval or marketing of these products for the indications being studied or for other indications;
that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results
to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce
results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials
may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<FONT STYLE="font-size: 8pt"><SUP>TM</SUP></FONT>&nbsp;product
line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.&nbsp;
In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological
and other factors discussed in Enlivex&rsquo;s filings with the Securities and Exchange Commission, including in the Company&rsquo;s
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.&nbsp; The forward-looking statements
contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to
update forward-looking statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>ENLIVEX CONTACT</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Shachar Shlosberger, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Enlivex Therapeutics, Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">shachar@enlivexpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
